Almirall, S.A. (ALMRY) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Armoural H1 2025 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1, 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Pablo Deverson, Head of Investor Relations. Please go ahead. Thank you very much, Heidi, and good morning, everyone. Thank you for joining us today's quarterly earnings update and review of Admiral's first half year financial results of 2025. As always, we are sharing the slide we are using today in the investor section of our website at admiral.com. Please move to slide number two. Let me remind you that the information presented in this call contains forward-looking statements which involve known and unknown risk, uncertainties, and other factors that may cause actual results to materially differ from what we are sharing today. Please move to slide number three. Presenting today are Carlos Gallardo, Chairman and Chief Executive Officer, Mike McGillan, Chief Financial Officer, Carl Ziegabar, Chief Scientific Officer, and we also have John Garay, our new CFO, joining us for the first time today. Carlos will start with the business highlights covering the first half of 2025, followed by an update especially on biologics, as the key co-drivers of our medical dermatology portfolio. Kai will provide you with the R&D status update regarding our pilot. And Mike will then tal...